

# PATHOLOGY GRAND ROUNDS



## Michael Mengel, MD

Chair and Professor  
Department of Laboratory Medicine  
and Pathology  
University of Alberta

## “Molecular Transplant Diagnostics and Why it is Different from Cancer”

Thursday, February 6th, 2020

12:30 p.m.

Fitkin Amphitheater – LMP 1094

Host: Gilbert Moeckel, MD, PhD



*There is no corporate or grant support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.*

### ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### TARGET AUDIENCE

Attending physicians, researchers, house staff, fellows, residents, medical students, nurses.

### NEEDS ASSESSMENT

Histopathological diagnosis of transplant pathology is based on consensus and hence associated with interobserver variability and ambiguity in subjectively applying association derived consensus diagnostic rules. Recent advances in molecular technologies

and insights into the pathogenesis and mechanisms of transplant rejection and associated pathologies offered the potential to address those shortcomings and to increase diagnostic precision in transplant pathology.

### LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Review the limitations of histopathology and the current Banff Classification for allograft pathology.
- Understand the association between histopathology and tissue based molecular assessment.
- Review the limitations of molecular transplant diagnostics.

- Discuss the potential applications of molecular diagnostics in routine transplant diagnostics.

### DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### FACULTY DISCLOSURES

Speaker Name: Michael Mengel - Novartis, Viatris, CSL Behring, Roche Diagnostics, Astra Zeneca.

Course Directors: Manju Prasad, MD - NONE

Kurt Schalper, MD, PhD - NONE

Gopal Pallavi, MD, PhD - NONE

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.